Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease

Current Medicinal Chemistry

Volumn 19, Issue 18, 2012, Pages 2918-2923

  Barbero Becerra, V J ^a,b   Santiago Hernandez, J J ^b   Villegas Lopez, F A ^b   Mendez Sanchez, N ^b   Uribe, M ^b   Chavez Tapia, N C ^b  

^a Fondazione Italiana Fegato ONLUS   (Italy)

^b Medica Sur Hospital and Clinical Foundation   (Mexico)

Author keywords

Biguanides; Insulin resistance; Liver diseases; Metabolic syndrome; Metabolism; Obesity

Indexed keywords

BIGUANIDE DERIVATIVE; BUFORMIN; GLUCOSE; METFORMIN; PHENFORMIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIVER PROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; WEIGHT REDUCTION;

EID: 84861845126     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800672094     Document Type: Review

References (45)

1. Kourelis, T.V.; Siegel, R.D., Metformin and cancer: new applications for an old drug. Med Oncol, 2011.
2. Anisimov, V.N., Metformin for aging and cancer prevention. Aging (Albany NY), 2010, 2, (11), 760-774.
3. Duvnjak, M.; Tomasic, V.; Gomercic, M.; Smircic Duvnjak, L.; Barsic, N.; Lerotic, I., Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol, 2009, 60 Suppl 7, 57-66.
4. Dowling, R.J.; Goodwin, P.J.; Stambolic, V., Understanding the benefit of metformin use in cancer treatment. BMC Med, 2011, 9, 33.
5. Miller, R.A.; Birnbaum, M.J., An energetic tale of AMPK-independent effects of metformin. J Clin Invest, 2010, 120, (7), 2267-2270.
6. Papanas, N.; Maltezos, E.; Mikhailidis, D.P., Metformin and cancer: licence to heal? Expert Opin Investig Drugs, 2010, 19, (8), 913-917.
7. Grisouard, J.; Timper, K.; Radimerski, T.M.; Frey, D.M.; Peterli, R.; Kola, B.; Korbonits, M.; Herrmann, P.; Krahenbuhl, S.; Zulewski, H.; Keller, U.; Muller, B.; Christ-Crain, M., Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol, 2010, 80, (11), 1736-1745.
8. Kaser, S.; Ebenbichler, C.F.; Tilg, H., Pharmacological and nonpharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract, 2010, 64, (7), 968-983.
9. Foretz, M.; Hebrard, S.; Leclerc, J.; Zarrinpashneh, E.; Soty, M.; Mithieux, G.; Sakamoto, K.; Andreelli, F.; Viollet, B., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest, 2010, 120, (7), 2355-2369.
10. Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S.H.; Bardeesy, N.; Depinho, R.A.; Montminy, M.; Cantley, L.C., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005, 310, (5754), 1642-1646.
11. Hardie, D.G., Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology, 2006, 131, (3), 973; author reply 974-975.
12. Jalving, M.; Gietema, J.A.; Lefrandt, J.D.; de Jong, S.; Reyners, A.K.; Gans, R.O.; de Vries, E.G., Metformin: taking away the candy for cancer? Eur J Cancer, 2010, 46, (13), 2369-2380.
13. Kalender, A.; Selvaraj, A.; Kim, S.Y.; Gulati, P.; Brule, S.; Viollet, B.; Kemp, B.E.; Bardeesy, N.; Dennis, P.; Schlager, J.J.; Marette, A.; Kozma, S.C.; Thomas, G., Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab, 2010, 11, (5), 390-401.
14. El-Mir, M.Y.; Nogueira, V.; Fontaine, E.; Averet, N.; Rigoulet, M.; Leverve, X., Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem, 2000, 275, (1), 223-228.
15. Owen, M.R.; Doran, E.; Halestrap, A.P., Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J, 2000, 348 Pt 3, 607-614.
16. Song, J.; Ren, P.; Zhang, L.; Wang, X.L.; Chen, L.; Shen, Y.H., Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun, 2010, 393, (1), 89-94.
17. Muntoni, S., Metformin and fatty acids. Diabetes Care, 1999, 22, (1), 179-180.
18. Bogachus, L.D.; Turcotte, L.P., Genetic downregulation of AMPK-alpha isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells. Am J Physiol Cell Physiol, 2010, 299, (6), C1549-1561.
19. Forcheron, F.; Abdallah, P.; Basset, A.; del Carmine, P.; Haffar, G.; Beylot, M., Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity (Silver Spring), 2009, 17, (7), 1381-1389.
20. Kim, E.; Liu, N.C.; Yu, I.C.; Lin, H.Y.; Lee, Y.F.; Sparks, J.D.; Chen, L.M.; Chang, C., Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes, 2011, 60, (5), 1493-1503.
21. Bourron, O.; Daval, M.; Hainault, I.; Hajduch, E.; Servant, J.M.; Gautier, J.F.; Ferre, P.; Foufelle, F., Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMPactivated protein kinase. Diabetologia, 2010, 53, (4), 768-778.
22. Jang, E.H.; Kim, H.K.; Park, C.S.; Kang, J.H., Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet, 2010, 25, (4), 392-397.
23. Caton, P.W.; Nayuni, N.K.; Kieswich, J.; Khan, N.Q.; Yaqoob, M.M.; Corder, R., Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol, 2010, 205, (1), 97-106.
24. Yanardag, R.; Ozsoy-Sacan, O.; Bolkent, S.; Orak, H.; Karabulut-Bulan, O., Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Hum Exp Toxicol, 2005, 24, (3), 129-135.
25. Bergheim, I.; Guo, L.; Davis, M.A.; Lambert, J.C.; Beier, J.I.; Duveau, I.; Luyendyk, J.P.; Roth, R.A.; Arteel, G.E., Metformin prevents alcoholinduced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology, 2006, 130, (7), 2099-2112.
26. Huang, Y.; Fu, J.F.; Shi, H.B.; Liu, L.R., [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. Zhonghua Er Ke Za Zhi, 2011, 49, (2), 139-145.
27. Qiang, G.F.; Zhang, L.; Xuan, Q.; Yang, X.Y.; Shi, L.L.; Zhang, H.A.; Chen, B.N.; Du, G.H., [Effect of metformin on the formation of hepatic fibrosis in type 2 diabetic rats]. Yao Xue Xue Bao, 2010, 45, (6), 801-806.
28. Tsoyi, K.; Jang, H.J.; Nizamutdinova, I.T.; Kim, Y.M.; Lee, Y.S.; Kim, H.J.; Seo, H.G.; Lee, J.H.; Chang, K.C., Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol, 2011, 162, (7), 1498-1508.
29. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.; Gao, B.; Wierzbicki, M.; Verbeuren, T.J.; Shaw, R.J.; Cohen, R.A.; Zang, M., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in dietinduced insulin-resistant mice. Cell Metab, 2011, 13, (4), 376-388.
30. Lin, H.Z.; Yang, S.Q.; Chuckaree, C.; Kuhajda, F.; Ronnet, G.; Diehl, A.M., Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 2000, 6, (9), 998-1003.
31. Bugianesi, E.; Gentilcore, E.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; David, E.; Rizzetto, M.; Marchesini, G., A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol, 2005, 100, (5), 1082-1090.
32. Sofer, E.; Boaz, M.; Matas, Z.; Mashavi, M.; Shargorodsky, M., Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism, 2011, 60, (9), 1278-1284.
33. Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Thumburu, K.T.; Bhadada, S.; Bhansali, A., Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol, 2007, 6, (4), 222-226.
34. Uygun, A.; Kadayifci, A.; Isik, A.T.; Ozgurtas, T.; Deveci, S.; Tuzun, A.; Yesilova, Z.; Gulsen, M.; Dagalp, K., Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2004, 19, (5), 537-544.
35. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Zoli, M.; Melchionda, N., Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, (9285), 893-894.
36. Nadeau, K.J.; Ehlers, L.B.; Zeitler, P.S.; Love-Osborne, K., Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes, 2009, 10, (1), 5-13.
37. Haukeland, J.W.; Konopski, Z.; Eggesbo, H.B.; von Volkmann, H.L.; Raschpichler, G.; Bjoro, K.; Haaland, T.; Loberg, E.M.; Birkeland, K., Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol, 2009, 44, (7), 853-860.
38. Loomba, R.; Lutchman, G.; Kleiner, D.E.; Ricks, M.; Feld, J.J.; Borg, B.B.; Modi, A.; Nagabhyru, P.; Sumner, A.E.; Liang, T.J.; Hoofnagle, J.H., Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2009, 29, (2), 172-182.
39. Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; Tonascia, J.; Unalp, A.; Clark, J.M.; Brunt, E.M.; Kleiner, D.E.; Hoofnagle, J.H.; Robuck, P.R., Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama, 2011, 305, (16), 1659-1668.
40. Tock, L.; Damaso, A.R.; de Piano, A.; Carnier, J.; Sanches, P.L.; Lederman, H.M.; Ernandes, R.M.; de Mello, M.T.; Tufik, S., Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents. J Obes, 2010, 2010.
41. Arkad'eva, A.V.; Mamonov, A.A.; Popovich, I.G.; Anisimov, V.N.; Mikhel'son, V.M.; Spivak, I.M., [Metformin slows down ageing processes at the cellular level in SHR mice]. Tsitologiia, 2011, 53, (2), 166-174.
42. Menendez, J.A.; Cufi, S.; Oliveras-Ferraros, C.; Vellon, L.; Joven, J.; Vazquez-Martin, A., Gerosuppressant metformin: less is more. Aging (Albany NY), 2011, 3, (4), 348-362.
43. Kim, H.G.; Hien, T.T.; Han, E.H.; Hwang, Y.P.; Choi, J.H.; Kang, K.W.; Kwon, K.I.; Kim, B.H.; Kim, S.K.; Song, G.Y.; Jeong, T.C.; Jeong, H.G., Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol, 2011, 162, (5), 1096-1108.
44. Hou, M.; Venier, N.; Sugar, L.; Musquera, M.; Pollak, M.; Kiss, A.; Fleshner, N.; Klotz, L.; Venkateswaran, V., Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun, 2010, 397, (3), 537-542.
45. Algire, C.; Amrein, L.; Zakikhani, M.; Panasci, L.; Pollak, M., Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer, 2010, 17, (2), 351-360.